Pharmacogenomics of CYP2C9: Functional and Clinical Considerations
Open accessThe DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most important contributor from this subfamily to drug metabolism. Polymorphisms resulting in decreased enzyme activity are common in the CYP2C9 gene and this, combined with narrow therapeutic indices for several key drug substrates, results in some important issues relating to drug safety and efficacy. CYP2C9 substrate selectivity is detailed and, based on crystal structures for the enzyme, we describe how CYP2C9 catalyzes these reactions. Factors relevant to clinical response to CYP2C9 substrates including inhibition, induction and genetic polymorphism are discussed in detail. In particular, we consider the issue of ethnic variation in pattern and frequency of genetic polymorphisms and clinical implications. Warfarin is the most well studied CYP2C9 substrate; recent work on use of dosing algorithms that include CYP2C9 genotype to improve patient safety during initiation of warfarin dosing are reviewed and prospects for their clinical implementation considered. Finally, we discuss a novel approach to cataloging the functional capabilities of rare ‘variants of uncertain significance’, which are increasingly detected as more exome and genome sequencing of diverse populations is conducted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587 · cited 2×
“org/) [84] provides comprehensive data on frequencies in a range of populations for a large number of CYP2C9 single nucleotide variants (SNVs).”
BackgroundMethodAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230 · cited 1×
“High INR values (>4) are a risk factor for bleeding, particularly in elderly patients [196] and warfarin related-adverse drug reactions of this type are a common cause of hospital admission [197].”
BackgroundEstimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577 · cited 1×
“To further improve ability to predict dose requirement and to cover a wider range of ethnicities, a joint project involving a large number of researchers worldwide (International Warfarin Pharmacogenetics Consortium (IWPC)) used clinical and genetic data on 4043 patients treated with warfarin to develop a more definit…”
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576 · cited 9×
“Similar to the findings for the −1188 variant alone, this haplotype did not affect warfarin or phenytoin dose requirement [86,112–114], but in vitro transcription studies indicated that reporter gene constructs including this haplotype may be associated with decreased responsiveness to both rifampicin and phenytoin wh…”
BackgroundInfluentialAithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243 · cited 3×
“1131 PolyPhen: possibly damaging; SIFT: deleterious; other: impaired S-warfarin and tolbutamide metabolism in vitro [78,79] and decreased warfarin dose in vivo [82]”
BackgroundSelf-citationGotoh, O. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48462-1 · Cited by 1,194 · cited 1×
“CYP2C9 structure showing substrate recognition sites (SRS) according to Gotoh [28].”
BackgroundCPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164 · cited 1×
“This term has been coined by the Clinical Pharmacogenetics Implementation consortium (CPIC), which has the goal ‘to help clinicians understand how available genetic test results should be used to optimize drug therapy’ [200].”
BackgroundHylek, E. M., Evans-Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,061 · cited 1×
“High INR values (>4) are a risk factor for bleeding, particularly in elderly patients [196] and warfarin related-adverse drug reactions of this type are a common cause of hospital admission [197].”
BackgroundHigashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
Self-citation
Cited by
Inhibition and induction of CYP enzymes in humans: an update
Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02936-7 · Cited by 418
Metadata
- Authors
- Daly, A., Rettie, A., Fowler, D., & Miners, J.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2017-12-28
- Volume
- 8
- Issue
- 1
- Pages
- 1
- ISSN
- 2075-4426 (ISSN-L)
- OpenAlex
- W2779604619
- Cited by
- 227
- References
- 169
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.